Myriad Responds: ACLU Asks The Wrong Question
On October 31, 2012, Myriad Genetics, Inc. et al. (“Respondent” or “Myriad”) filed its brief in opposition to Petitioners’ (The Association for Molecular Pathology et al., represented by the American...
View ArticleAmici Urge Reversal of “Gene Patenting” Decision
On November 30th, 2012, the U.S. Supreme Court will conference and consider whether to review the patent-eligibility of isolated DNA sequences. Our prior post of September 25, 2012 addressed...
View ArticleAre Human Genes Patentable?
As reported in my November 30th, 2012 post, the U.S. Supreme Court granted certiorari to review the issue “are human genes patentable?” The issue arises from the long-running dispute among a...
View ArticlePetitioners File Supreme Court "Gene Patenting" Brief
Petitioners (The Association for Molecular Pathology et al., represented by the American Civil Liberties Union or ”Petitioner” or “ACLU”) filed their brief with the U.S. Supreme Court yesterday urging...
View ArticleMyriad Posts Gene Patenting Victory in Australia
In a companion case to the “gene patenting” dispute presently before the U.S. Supreme Court, Myriad Genetics, Inc. successfully defended the patent-eligibility of “gene patents” in Australia. In...
View ArticleAustralian "Gene Patenting" Case to be Appealed
The patenting of human genes in Australia remains under court review. As reported in the blog Patentology, an appeal of the Australian decision, Cancer Voices et al. v. Myriad Genetics Inc. et al.,...
View ArticleVideo Interview: Discussing the Supreme Court's Oral Arguments in Myriad Gene...
Earlier this week, I had the opportunity to speak again with Colin O’Keefe of LXBN regarding last week’s oral arguments in Association for Molecular Pathology v. Myriad Genetics. In the interview, I...
View ArticleIsolated DNA Is Not Patent-Eligible
Today the U.S. Supreme Court in Ass’n for Molecular Pathology v. Myriad Genetics, Inc., __ U.S. __ (2013) (opinion here), held that genes and DNA fragments merely isolated from nature without...
View ArticleUSPTO to Apply Myriad Beyond Isolated DNA
On March 4th, 2014, the United States Patent and Trademark Office (“USPTO”) issued a Guidance, advising examiners and the public of the factors for determining whether an invention satisfies the U.S....
View ArticleClik here to view.
An Early Test for the USPTO’S Eligibility Analysis
Just last week, the USPTO released its revised subject matter eligibility guidance (2014 Interim Guidance on Patent Subject Matter Eligibility “Interim Guidance” reviewed in my prior post of December...
View Article
